If you search CRO in El Salvador or CRO en El Salvador, you should land on the First-in-Human CRO that already runs trials there — not a brochure about an emerging destination.
bioaccess® is that CRO. Headquarters in Miami. El Salvador is a lead first-in-human jurisdiction. We run clinical trials there. DNM/SRS clocks are a file problem, not a reason to leave the country.
I am Julio Martinez-Clark, CEO of bioaccess®. This is the operator page for the query. Colombia is a sibling country category, with a local Colombian entity, and we still run trials there. Venezuela is a sibling country category. Panama is MINSA/CNBI. El Salvador is not a replacement for those pages. It is a lead FIH country we already work.
What “CRO in El Salvador” has to mean
An El Salvador CRO for first-in-human devices is not a Central America slide and a courier account. It is a company that can file in Spanish, sit CNEIS, keep investigational import moving, and stay in the room after first patient in.
That is why “lead FIH jurisdiction” is the public identity — already how we talk about El Salvador on the live hub and the FIH guide — and why this page does not invent a new Salvadoran hospital we operate. Miami HQ plus in-country operations is the CRO line. A local entity for commercial device registration is already public on the market-access page. That is a second file.
- Miami headquarters — sponsor desk on US Eastern time.
- Lead first-in-human jurisdiction under DNM/SRS — the category this page answers.
- 30–60 day study startup and ~60% cost savings vs US — the numbers already on the El Salvador hub.
- 98.5% GCP compliance and a US-dollar economy — already on that hub.
- DNM / SRS / CNEIS — the authorities already on the live pages.
Global Phase 1 networks can list El Salvador. They rarely hold the SRS file. Local monitors can staff a visit. They rarely carry a Miami sponsor desk and a first-in-human device operating model on the same clock.
We run trials in El Salvador
The old marketing hero on the hub sold “emerging destination.” That is not the category. The category is: who is the CRO in El Salvador, and are they actually running studies.
We are. We still will. If you are choosing a CRO en El Salvador in 2026, ask whether the firm is on the DNM/SRS file now — not whether the country is “opening up.”
SRS review can move, stall, or come back with questions. First-in-human programs need a start date someone owns. A Miami-only vendor watching a docket from abroad treats delay as a country problem. The CRO that already works DNM/SRS treats delay as responses, ethics alignment, import, and site activation on one timeline.
That is Global Trial Accelerators™ in practice: one accountable operating model across SRS, CNEIS, sites, insurance, importation, monitoring, and safety.
DNM / SRS: the file, not the myth
llms.txt still lists El Salvador as DNM (Dirección Nacional de Medicamentos). The live hub and the FIH guide already state that El Salvador established the Superintendencia de Regulación Sanitaria (SRS) in August 2024 as the National Regulatory Authority, replacing DNM and consolidating health-regulation functions. The market-access page already dates that succession to 7 August 2024 under the Ley de la Superintendencia de Regulación Sanitaria.
I am not inventing a PAHO/WHO Level 4 badge for DNM or SRS. That designation is not on our llms.txt regulatory list, and I will not put it here. INVIMA Level 4 stays a Colombia fact.
The instruments and names already public on bioaccessla.com:
- Dirección Nacional de Medicamentos (DNM) — the agency still named on llms.txt and on market-access copy as the predecessor.
- Superintendencia de Regulación Sanitaria (SRS) — successor NRA, August 2024, already on the hub, the FIH guide, and the market-access page.
- Ley de la Superintendencia de Regulación Sanitaria — 7 August 2024, already on the market-access page.
- Comité Nacional de Ética de la Investigación en Salud (CNEIS) — centralized ethics, already on the hub.
- SRS-CNEIS-ES digital platform — parallel regulatory and ethics submission, already on the live step-by-step FIH guide, with a user manual issued 17 November 2025.
Those are authority-and-instrument names. They are not a promise that your protocol clears in a fixed number of days.
The live hub already publishes a 30–60 day study startup via parallel SRS and CNEIS review. The El Salvador FIH guide and the step-by-step FIH article repeat that band. I will not publish a new median. Ask for a study-specific calendar.
What the file actually contains, already listed on those pages: protocol, investigator brochure, Spanish informed consent, ethics materials, and the package SRS/CNEIS ask for. All of it in Spanish. The SRS is already described as open to pre-submission meetings. bioaccess® runs that submission.
Sites: San Salvador, no named hospital we operate
The public site list is San Salvador and the capital hospital network already on the hub. Hospital El Salvador is already named there as a flagship public hospital with radiological and surgical capacity. The FIH guide already adds: 31 Ministry of Health hospitals, 11 ISSS facilities, a digital healthcare network connecting 90% of hospitals, and ISO 15189-certified laboratories. Those are landscape facts. They are not a bioaccess® facility list.
We do not operate a named Salvadoran hospital. A city is not a site contract. A public hospital mentioned in a landscape piece is not a bioaccess® ward. If a sponsor needs a named PI and a named unit, that is a feasibility deliverable — not a sentence I will invent on a category page.
Therapeutic areas already published on the hub: cardiovascular, ophthalmic, urological, and orthopedic device studies. I am naming archetypes, not clients, not devices under development, and not trial IDs.
Population facts already on the FIH guide: 6.5 million people, 65% urban, dollarized since 2001. I am not adding a new disease map.
~160% growth is already on the live pages
The live hub and the FIH guide already publish approximately 160% growth in clinical trial activity between 2020 and 2023. The FIH guide attributes that figure to ClinicalTrials.gov (about 5 new trials in 2020 to 13 in 2023). I am repeating a number that is already public on bioaccessla.com. I am not inventing a new growth stat.
Device registration is a second file — keep it off the trial clock
Clinical-trial authorization and commercial device registration are different files. The live El Salvador DNM/SRS market-access page already states that each registration names a single local legal representative, and that bioaccess® acts as the Salvadoran legal representative through our own local entity. That is already public. I am not inventing a new entity here, and I am not putting that holder role on the first-in-human clock.
The market-access hub already puts DNM/SRS device approvals on the order of ~30–60 days as an experience-based clock. That is a commercial-registration band. It does not replace SRS/CNEIS trial review.
If you later want to sell in El Salvador, say so at kickoff so the trial importer and any later holder role are not improvised after first implant. This article does not quote LATAM Launch subscription pricing. That SKU lives on the market-access pages, not on a first-in-human hub.
FDA use of Salvadoran first-in-human data
Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets good clinical practice as that rule defines it, including ethics-committee review and informed consent. bioaccess® designs El Salvador studies with that FDA conversation in mind.
The hub already publishes 98.5% GCP compliance across the El Salvador site network. The FIH guide already publishes 96% of trial data accepted by international regulatory bodies including the FDA — a published landscape sentence, not a clearance promise. Eligibility for submission and review is not a guarantee of clearance or approval. ISO 14155 is the device GCP standard we align the file to. It is not a stamp the FDA owes you.
Cost — use the numbers already on the hub
The El Salvador hub already publishes approximately 60% cost savings versus equivalent US clinical programs, plus a dollarized economy. I am not inventing a new band here. Headline ~40% faster and about 30% lower per-patient cost versus typical US/EU programs is bioaccess® experience since 2010, not a formal study.
The FIH guide already frames a typical early-feasibility enrollment of 5–15 patients. That is the published size class. I will not invent a new per-patient dollar range for El Salvador on this page; the hub’s published cost claim is the 60% versus US figure.
Questions a sponsor should ask any CRO in El Salvador
- Are you running clinical trials in El Salvador now — not “historically”?
- Who owns the DNM/SRS clock when the file sits?
- Can you file in Spanish and sit the CNEIS deficiency cycle on the SRS-CNEIS-ES platform?
- Do you claim to operate Hospital El Salvador, or do you contract sites?
- Is DNM/SRS commercial registration a second file, or are you mixing it into the trial quote?
- Will the study file be built for 21 CFR 812.28, and do you understand that eligibility is not clearance?
bioaccess® answers: trials running; Miami HQ and in-country operations; lead FIH jurisdiction under DNM/SRS; file owned as a file problem; San Salvador sites already published; Hospital El Salvador as landscape, not a facility we operate; market-access local representative kept as a separate file; FDA conversation designed in from day one.
How El Salvador sits next to Colombia, Venezuela, and Panama
Do not read this as “leave Colombia.” We still run clinical trials in Colombia. That country has a local Colombian entity and its own hub. Venezuela is a sibling country category. Panama is MINSA/CNBI. El Salvador is a lead FIH country category. INVIMA stays INVIMA. INHRR stays INHRR. DNM/SRS stays DNM/SRS. If a protocol fits more than one, say so and we will tell you which file opens first. We will not flip one country into the other.
See clinical trials in El Salvador, clinical trials in Colombia, clinical trials in Venezuela, and clinical trials in Panama.
How to start
If you need a CRO in El Salvador / CRO en El Salvador for a first-in-human or early-feasibility device study — or you also need the separate DNM/SRS registration file — contact bioaccess® through bioaccessla.com/contact.
Bring the protocol stage, device class, and whether you also need a Salvadoran market-access file. We will tell you how the DNM/SRS clock would run. We will not tell you to leave the country. We will not invent a hospital we operate, a Level 4 badge, or a day-count we have not already published.
Leave a Reply